FIP1L1-PDGFRA Gene Rearrangement Detection Test
Comprehensive Genetic Analysis for Blood Disorders
The FIP1L1-PDGFRA Gene Rearrangement Detection Test represents a breakthrough in molecular diagnostics for hematological malignancies. This advanced genetic test specifically identifies the fusion between FIP1L1 and PDGFRA genes, a critical genetic abnormality associated with certain forms of hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia.
What This Test Measures
This sophisticated PCR-based test detects the presence of the FIP1L1-PDGFRA fusion gene, which results from an interstitial deletion on chromosome 4q12. The rearrangement creates a constitutively active tyrosine kinase that drives abnormal cell proliferation and survival, leading to persistent eosinophilia and potential progression to more serious hematological conditions.
- Detection of FIP1L1-PDGFRA fusion gene
- Identification of specific genetic rearrangements
- Assessment of molecular markers for targeted therapy
- Evaluation of genetic basis for eosinophilic disorders
Who Should Consider This Test
This test is recommended for individuals presenting with:
- Unexplained persistent eosinophilia (eosinophil count >1.5 × 10⁹/L)
- Symptoms of hypereosinophilic syndrome
- Organ damage related to eosinophil infiltration
- Resistance to conventional eosinophilia treatments
- Suspected chronic eosinophilic leukemia
- Family history of hematological disorders
Clinical Benefits of Testing
Early detection through the FIP1L1-PDGFRA Gene Rearrangement Test provides numerous clinical advantages:
- Targeted Therapy Guidance: Positive results indicate potential responsiveness to tyrosine kinase inhibitors like imatinib
- Accurate Diagnosis: Helps differentiate between various eosinophilic disorders
- Treatment Optimization: Enables personalized treatment strategies
- Prognostic Information: Provides insights into disease progression and outcomes
- Cost-Effective Management: Avoids unnecessary treatments and their associated side effects
Understanding Your Test Results
Your test results will fall into one of two categories:
Positive Result
A positive result indicates the presence of the FIP1L1-PDGFRA fusion gene. This finding suggests that your condition may respond well to targeted therapy with tyrosine kinase inhibitors. Your healthcare provider will discuss appropriate treatment options and develop a comprehensive management plan.
Negative Result
A negative result means the FIP1L1-PDGFRA fusion gene was not detected. This information helps your physician explore alternative diagnoses and treatment approaches for your eosinophilic condition.
Test Pricing Information
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $262 |
| Regular Price | $376 |
Sample Requirements and Processing
For accurate testing, we require:
- 4 mL (2 mL minimum) whole blood or bone marrow
- Collected in 1 Lavender Top (EDTA) tube
- Ship refrigerated – DO NOT FREEZE
- Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory
Turnaround Time: Sample must be received by Monday 11 am; Report available in 12 days
Nationwide Testing Availability
We have branches across the United States, including major cities like New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our extensive network ensures convenient access to this advanced genetic testing service.
Take Control of Your Health Today
Don’t let unexplained symptoms go undiagnosed. The FIP1L1-PDGFRA Gene Rearrangement Detection Test provides critical genetic information that can transform your treatment journey. Our expert team is ready to assist you with comprehensive genetic analysis and personalized care.
Book your test now or call our genetic specialists at +1(267) 388-9828 to schedule your appointment and take the first step toward precise diagnosis and targeted treatment.
